BACKGROUND:Patient navigation is a promising intervention to ameliorate cancer health disparities. This study objective was to measure patient navigation effects on cancer-specific quality of life (QOL) among patients with newly diagnosed cancer. METHODS: A randomized controlled trial of patient navigation was conducted in Rochester, NY. Patients with breast cancer and colorectal cancer were randomly assigned to receive a patient navigation intervention or usual care. QOL was measured at baseline and four subsequent time points, using the validated Functional Assessment of Cancer Therapy (FACT-B, FACT-C) instruments. RESULTS: Among 319 randomized patients (165 patient navigation, 154 control), median age was 57 years and 32.5% were from minority race/ethnicity groups. Patient navigation and control groups were comparable on baseline factors, except home ownership versus renting (more home ownership among controls, P = 0.05) and race (more whites among controls, P = 0.05). Total and subscale FACT scores did not differ between groups when analyzed as a change from baseline to 3 months, or at various time points. The emotional well-being subscale change from baseline approached significance (better change among patient navigation group, P = 0.05). Time trends of QOL measures did not differ significantly between groups. Adjustment for baseline patient factors did not reveal a benefit of patient navigation on QOL. CONCLUSIONS: In this randomized trial of patient navigation, there was no statistically significant effect on disease-specific QOL. IMPACT: These results suggest that patient navigation may not affect QOL during cancer treatment, that social/medical support are adequate in this study's setting, or that the trial failed to target patients likely to experience QOL benefit from patient navigation. 2012AACR
RCT Entities:
BACKGROUND:Patient navigation is a promising intervention to ameliorate cancer health disparities. This study objective was to measure patient navigation effects on cancer-specific quality of life (QOL) among patients with newly diagnosed cancer. METHODS: A randomized controlled trial of patient navigation was conducted in Rochester, NY. Patients with breast cancer and colorectal cancer were randomly assigned to receive a patient navigation intervention or usual care. QOL was measured at baseline and four subsequent time points, using the validated Functional Assessment of Cancer Therapy (FACT-B, FACT-C) instruments. RESULTS: Among 319 randomized patients (165 patient navigation, 154 control), median age was 57 years and 32.5% were from minority race/ethnicity groups. Patient navigation and control groups were comparable on baseline factors, except home ownership versus renting (more home ownership among controls, P = 0.05) and race (more whites among controls, P = 0.05). Total and subscale FACT scores did not differ between groups when analyzed as a change from baseline to 3 months, or at various time points. The emotional well-being subscale change from baseline approached significance (better change among patient navigation group, P = 0.05). Time trends of QOL measures did not differ significantly between groups. Adjustment for baseline patient factors did not reveal a benefit of patient navigation on QOL. CONCLUSIONS: In this randomized trial of patient navigation, there was no statistically significant effect on disease-specific QOL. IMPACT: These results suggest that patient navigation may not affect QOL during cancer treatment, that social/medical support are adequate in this study's setting, or that the trial failed to target patients likely to experience QOL benefit from patient navigation. 2012 AACR
Authors: Samantha K Hendren; Brenda I O'Connor; Maria Liu; Tracey Asano; Zane Cohen; Carol J Swallow; Helen M Macrae; Robert Gryfe; Robin S McLeod Journal: Ann Surg Date: 2005-08 Impact factor: 12.969
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Karen M Freund; Tracy A Battaglia; Elizabeth Calhoun; Donald J Dudley; Kevin Fiscella; Electra Paskett; Peter C Raich; Richard G Roetzheim Journal: Cancer Date: 2008-12-15 Impact factor: 6.860
Authors: Kristen J Wells; Tracy A Battaglia; Donald J Dudley; Roland Garcia; Amanda Greene; Elizabeth Calhoun; Jeanne S Mandelblatt; Electra D Paskett; Peter C Raich Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: Horia Vulpe; Janet Ellis; Shao Hui Huang; Eshetu G Atenafu; Raymond W Jang; Gary Rodin; Jolie Ringash Journal: Support Care Cancer Date: 2016-11-04 Impact factor: 3.603
Authors: Kristen J Wells; Paul C Winters; Pascal Jean-Pierre; Victoria Warren-Mears; Douglas Post; Mary Ann S Van Duyn; Kevin Fiscella; Julie Darnell; Karen M Freund Journal: Support Care Cancer Date: 2015-10-05 Impact factor: 3.603
Authors: Pamela Samson; Aalok Patel; Tasha Garrett; Traves Crabtree; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Varun Puri Journal: Ann Thorac Surg Date: 2015-04-16 Impact factor: 4.330
Authors: Catherine E Mosher; Joseph G Winger; Barbara A Given; Safi Shahda; Paul R Helft Journal: Support Care Cancer Date: 2017-04-22 Impact factor: 3.603
Authors: Jesse J Plascak; Adana A Llanos; Michael L Pennell; Rory C Weier; Electra D Paskett Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-09-09 Impact factor: 4.254
Authors: Mark E Bensink; Scott D Ramsey; Tracy Battaglia; Kevin Fiscella; Thelma C Hurd; June M McKoy; Steven R Patierno; Peter C Raich; Eric E Seiber; Victoria Warren-Mears; Elizabeth Whitley; Electra D Paskett; S Mandelblatt Journal: Cancer Date: 2013-10-25 Impact factor: 6.860